CAPLIPOINT Caplin Point Laboratories Q3 FY26 results (Oct–Dec 2025) and concall
Caplin Point Laboratories reported a strong Q3 FY26, driven by robust revenue growth, significant margin expansion, and impressive PAT growth that surpassed the full FY24 figures. The company saw continued traction in its US label business and made progress in its product pipeline and capacity expansion. While some projects faced delays, management expressed confidence in future growth from new markets and products, supported by healthy cash reserves and strategic capital allocation.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 10.1%, net profit up 18.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 483 | 493 | 502 | 510 | 534 +11% | 543 +10% |
| EBITDA | 165 | 162 | 168 | 178 | 189 +15% | 190 +17% |
| Net profit | 131 | 140 | 145 | 151 | 160 +22% | 166 +19% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
